{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":67,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":67,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"3a64bb924a83","filters":{"venue":"Canadian Hematology Today"}},"results":[{"id":"W4384463907","doi":"10.58931/cht.2022.117","title":"Myeloproliferative neoplasms in 2022","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Polycythemia vera; Essential thrombocythemia; Ruxolitinib; Myelofibrosis; Myeloid leukemia; Medicine; Janus kinase 2; Oncology; Disease; Janus kinase; Internal medicine; Stem cell; Haematopoiesis; Immunology; Myeloproliferative Disorders; Myeloproliferative neoplasm; Myeloid; Cancer research; Bone marrow; Biology; Cytokine; Receptor","authors":[{"name":"Dawn Maze","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0119502008260812,"gpt":0.2499592666882276,"spread":0.2380090658621464,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001429929,0.0002291531,0.0001569563,0.0005656354,0.0007479132,0.0005112347,0.0001614049,0.0004413568,0.02935905],"category_scores_gemma":[0.0004693844,0.00006234652,0.0001136475,0.0005567834,0.0001784638,0.0002360316,0.0004232605,0.0004474163,0.006033869],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008352284,"about_ca_system_score_gemma":0.001667072,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00935619,"about_ca_topic_score_gemma":0.01978924,"domain_scores_codex":[0.9998711,0.00001224929,0.000008771504,0.00001195636,0.00004912278,0.00004671428],"domain_scores_gemma":[0.9998525,0.0000132655,0.00001680357,0.000005251472,0.00004306989,0.00006912472],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005363848,0.0003324075,0.1022902,0.0006965153,0.00003790951,0.04325863,0.0006243351,0.0002198084,0.01035537,0.01633104,0.224924,0.6003935],"study_design_scores_gemma":[0.00005314994,0.0000941827,0.06845712,0.0003770728,0.00002332264,0.06595727,0.0003059751,0.0001164946,0.001428762,0.001821533,0.8613539,0.0000112505],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"review","genre_scores_codex":[0.1524896,0.0692995,0.001884389,0.01246939,0.00344164,0.0005052347,0.004637387,0.0003577488,0.7549152],"genre_scores_gemma":[0.6554714,0.03272657,0.002801712,0.00931311,0.002352548,0.0002105009,0.005668754,0.00006086031,0.2913945],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.02935905,"threshold_uncertainty_score":0.09821576,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4409993746","doi":"10.58931/cht.2025.4166","title":"Hemophagocytic Lymphohistiocytosis and Other Cytokine Storm Syndromes in Adults","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University; University of British Columbia","funders":"Dalhousie University","keywords":"Hemophagocytic lymphohistiocytosis; Cytokine storm; Medicine; Storm; Immunology; Geography; Meteorology; Internal medicine; Coronavirus disease 2019 (COVID-19); Disease","authors":[{"name":"Mariam Goubran","is_ca":true},{"name":"Luke Y. C. Chen","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01264928756112839,"gpt":0.2741008994893592,"spread":0.2614516119282308,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000131271,0.0004622124,0.0003827111,0.0006196001,0.0003648164,0.0003382599,0.0001685426,0.0004933131,0.002199861],"category_scores_gemma":[0.0006175108,0.0001366978,0.0002399288,0.0006342225,0.0002487826,0.0005157093,0.0004096465,0.0005087415,0.0005661724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002097606,"about_ca_system_score_gemma":0.0002543147,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007732224,"about_ca_topic_score_gemma":0.0006479884,"domain_scores_codex":[0.9998677,0.00001810157,0.00001821646,0.0000303881,0.00002691066,0.00003859254],"domain_scores_gemma":[0.9998294,0.0000266828,0.00005840367,0.000008274907,0.0000223466,0.00005486492],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00093502,0.0001366768,0.4925305,0.0007402431,0.0001291138,0.3468424,0.001055297,0.0004019389,0.0196905,0.003829191,0.01393551,0.1197736],"study_design_scores_gemma":[0.00005970726,0.0002763299,0.1855825,0.0003978339,0.00007756794,0.7878272,0.0003220003,0.0003102819,0.001489535,0.002009015,0.02162148,0.00002662638],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.8802699,0.06811068,0.005109697,0.001836502,0.0002916114,0.0002567098,0.001371646,0.0003771227,0.04237601],"genre_scores_gemma":[0.9830716,0.01074857,0.001194377,0.0007797444,0.0002927384,0.00005839946,0.0009371346,0.00001799871,0.002899393],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.002199861,"threshold_uncertainty_score":0.007359266,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384460914","doi":"10.58931/cht.2023.2s0736","title":"Navigating challenging treatment decisions in relapsed and refractory multiple myeloma (RRMM)","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Université de Sherbrooke; London Health Sciences Centre; Western University","funders":"University of British Columbia; University of Ottawa; University of Alberta; University of Calgary","keywords":"Medicine; Multiple myeloma; Intensive care medicine; Refractory (planetary science); Oncology; Clinical trial; Internal medicine","authors":[{"name":"Martha Louzada","is_ca":true},{"name":"Arleigh McCurdy","is_ca":true},{"name":"Michel Pavic","is_ca":true},{"name":"Christopher P. Venner","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0474630905079517,"gpt":0.3348810642120623,"spread":0.2874179737041106,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01811217,0.000466598,0.001545624,0.001625073,0.00734144,0.01139256,0.002324131,0.004310615,0.007428334],"category_scores_gemma":[0.06549944,0.000623538,0.001038278,0.001446662,0.004623782,0.005759687,0.006961475,0.01479407,0.001806304],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01051938,"about_ca_system_score_gemma":0.03916446,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02905318,"about_ca_topic_score_gemma":0.07850885,"domain_scores_codex":[0.9847693,0.01004922,0.00077515,0.001108402,0.00178464,0.001513318],"domain_scores_gemma":[0.9623794,0.01787842,0.003866344,0.0006232077,0.004321665,0.01093095],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006368804,0.0004495472,0.02222633,0.001400526,0.0004476353,0.002840343,0.01108595,0.004830406,0.0006670352,0.03357073,0.4344966,0.4873481],"study_design_scores_gemma":[0.0004061691,0.000564117,0.01499877,0.005438119,0.0004535799,0.003626682,0.03127098,0.007394714,0.0008906314,0.3535556,0.5809082,0.0004925763],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0422425,0.04576036,0.01420534,0.857394,0.004317938,0.0002854754,0.0004758262,0.000303369,0.03501515],"genre_scores_gemma":[0.5895736,0.0801602,0.07758879,0.2290282,0.01378067,0.0004982225,0.001130825,0.0005415452,0.007697996],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.9709468,"threshold_uncertainty_score":0.09578747,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384461310","doi":"10.58931/cht.2023.2s0326","title":"A review of the mechanism of action, safety, and efficacy of selinexor in multiple myeloma","year":2023,"lang":"en","type":"review","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Lenalidomide; Carfilzomib; Bortezomib; Pomalidomide; Multiple myeloma; Medicine; Dexamethasone; Oncology; Pharmacology; Mechanism of action; Drug; Internal medicine; Chemistry","authors":[{"name":"Christine Chen","is_ca":false},{"name":"Paola Neri","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09048699920866078,"gpt":0.3722251790517971,"spread":0.2817381798431364,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006716266,0.0006769894,0.001416311,0.002189279,0.0002416061,0.0008579293,0.0007188609,0.0006669902,0.004275735],"category_scores_gemma":[0.001031351,0.0003284844,0.001107707,0.001804066,0.0002531805,0.001031082,0.0003951672,0.001242471,0.001183552],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004818164,"about_ca_system_score_gemma":0.0008942347,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001119179,"about_ca_topic_score_gemma":0.001895961,"domain_scores_codex":[0.9997334,0.00005096991,0.00006899847,0.00004462436,0.00008497849,0.00001700745],"domain_scores_gemma":[0.9995664,0.0002453668,0.00008504909,0.000008650833,0.00007321768,0.00002137976],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002204413,0.0001134967,0.0002243234,0.07953499,0.0003238193,0.0003130196,0.0001243923,0.0004569372,0.002583943,0.001888538,0.03918036,0.8750358],"study_design_scores_gemma":[0.00004420091,0.0003976501,0.001407799,0.01717271,0.0006141212,0.001614714,0.00005569425,0.0001143607,0.0005370101,0.0008413645,0.9771722,0.00002824041],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001455738,0.9988342,0.00007320034,0.0001463534,0.0001235807,0.000007934156,0.00003364364,0.000005603622,0.000629869],"genre_scores_gemma":[0.0006543125,0.9983924,0.0001595478,0.0002325581,0.0001466748,0.00001087624,0.00004521275,0.000001429758,0.0003569581],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9988808,"threshold_uncertainty_score":0.01430374,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4406091238","doi":"10.58931/cht.2024.3360","title":"Minimal Residual Disease in Myeloma in 2024: Where We are Today","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Capital District Health Authority","funders":"","keywords":"Minimal residual disease; Multiple myeloma; Residual; Disease; Medicine; Computer science; Internal medicine; Algorithm; Bone marrow","authors":[{"name":"Alfredo De La Torre","is_ca":true},{"name":"Ana-Florencia Ramírez Ibarguen","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02206489221781091,"gpt":0.2981387095859397,"spread":0.2760738173681289,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001656231,0.0003515586,0.000899129,0.001202104,0.001512077,0.003137182,0.0009271079,0.001928995,0.005588568],"category_scores_gemma":[0.003060091,0.0002066702,0.0003513448,0.001646065,0.001581085,0.002436188,0.001796826,0.003517184,0.002148705],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003443943,"about_ca_system_score_gemma":0.005515179,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02958282,"about_ca_topic_score_gemma":0.04598691,"domain_scores_codex":[0.9991393,0.0001690793,0.00009706567,0.0000977216,0.0003209915,0.0001758249],"domain_scores_gemma":[0.9987904,0.0001495061,0.0002394296,0.00006020831,0.0004020172,0.0003584348],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006692699,0.000112395,0.02890633,0.00212135,0.00008059025,0.00478697,0.001506189,0.0001861317,0.004445975,0.02901346,0.3109005,0.6172709],"study_design_scores_gemma":[0.00004420759,0.0001545844,0.02664696,0.002167793,0.00008664841,0.01498374,0.001362658,0.000131658,0.0009876095,0.01184371,0.9415237,0.00006670444],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"other","genre_scores_codex":[0.02170842,0.7424003,0.003649969,0.1602302,0.01107941,0.0001271897,0.0009164127,0.0003683722,0.05951985],"genre_scores_gemma":[0.3175826,0.4936745,0.01248189,0.0926418,0.02386083,0.0001697882,0.002739175,0.0002769572,0.05657256],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.02958282,"threshold_uncertainty_score":0.05882126,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4292497528","doi":"10.58931/cht.2022.119","title":"To transplant or not to transplant in multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Melphalan; Transplantation; Autologous stem-cell transplantation; Internal medicine; Oncology; Hematopoietic stem cell transplantation; Stem cell; Surgery; Chemotherapy","authors":[{"name":"Richard LeBlanc","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03829346955218348,"gpt":0.2977335464162181,"spread":0.2594400768640346,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009905414,0.0001759387,0.0004520081,0.0003408925,0.0006669394,0.0009550966,0.0003723916,0.001067138,0.01691677],"category_scores_gemma":[0.002839261,0.00006350553,0.000511495,0.0005147794,0.0003578454,0.0009211141,0.000649351,0.002134091,0.002901309],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005050554,"about_ca_system_score_gemma":0.0006233509,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003667486,"about_ca_topic_score_gemma":0.001183285,"domain_scores_codex":[0.9995956,0.0001552497,0.00004882373,0.00005133849,0.00007147909,0.00007744426],"domain_scores_gemma":[0.9991544,0.0003037339,0.0001636529,0.00003738255,0.00006786235,0.000272911],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001976634,0.0005840777,0.02260841,0.002800002,0.0002672931,0.002187186,0.0004259734,0.0004211171,0.001512775,0.008118925,0.08885498,0.8702427],"study_design_scores_gemma":[0.0008342958,0.003084127,0.07275421,0.009736718,0.001009531,0.02904385,0.000991333,0.0007697663,0.00198756,0.03282787,0.8468109,0.0001497993],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"commentary","genre_scores_codex":[0.1445029,0.5920866,0.0104076,0.09329817,0.02143252,0.0004414777,0.00274677,0.0003934778,0.1346904],"genre_scores_gemma":[0.659171,0.1984845,0.006255173,0.07572927,0.02911292,0.00059914,0.003718928,0.0002546381,0.02667443],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.01691677,"threshold_uncertainty_score":0.05659229,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4403602474","doi":"10.58931/cht.2023.2338","title":"Bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for indolent lymphoma","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Chimeric antigen receptor; Lymphoma; Antibody; Bispecific antibody; Antigen; Medicine; Virology; Immunology; Antibody therapy; Cancer research; Immunotherapy; Monoclonal antibody; Immune system","authors":[{"name":"Isabelle Fleury","is_ca":true},{"name":"Eva Laverdure","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0350963459906627,"gpt":0.3005168672949186,"spread":0.2654205213042559,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002156809,0.0001869568,0.0002028355,0.0004618297,0.0001387612,0.0002145651,0.0002560882,0.0003403215,0.002848529],"category_scores_gemma":[0.0001596627,0.00004435947,0.0001642158,0.0002930271,0.0002092848,0.0001976566,0.0001967996,0.0005400334,0.0007626452],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006546823,"about_ca_system_score_gemma":0.0005578128,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003314852,"about_ca_topic_score_gemma":0.00683921,"domain_scores_codex":[0.9999241,0.00001707982,0.00000359465,0.000007287394,0.00002582877,0.00002214143],"domain_scores_gemma":[0.9999608,0.000008295891,0.000008265008,0.000002422083,0.000006512998,0.00001370688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002313714,0.001237719,0.002753281,0.0006377336,0.00008008783,0.001147474,0.00009421258,0.001788845,0.0582488,0.008206646,0.0195932,0.9038985],"study_design_scores_gemma":[0.003397681,0.01613839,0.0367074,0.0003760683,0.0003164716,0.01029129,0.0001402957,0.004264766,0.07470851,0.005919771,0.8476791,0.00006034113],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.4700958,0.4091318,0.01403073,0.007591908,0.001246233,0.0005210103,0.0006849621,0.0007991052,0.0958985],"genre_scores_gemma":[0.8488116,0.1169105,0.006458211,0.002700342,0.000476192,0.0002050504,0.0009583432,0.00004328967,0.02343657],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.003314852,"threshold_uncertainty_score":0.009529293,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384274095","doi":"10.58931/cht.2022.1320","title":"Chronic Myeloid Leukemia: who should get a treatment-free trial and how?","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Discontinuation; Chronic myelogenous leukemia; Life expectancy; Clinical trial; Oncology; Internal medicine; Quality of life (healthcare); Leukemia; Intensive care medicine; Population; Nursing","authors":[{"name":"Sarit Assouline","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02688000657122393,"gpt":0.2643091174620462,"spread":0.2374291108908223,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.056393,0.0007112205,0.003428041,0.001757487,0.004923812,0.01511737,0.003318047,0.01699793,0.03207112],"category_scores_gemma":[0.1303203,0.0005932327,0.001625741,0.002436077,0.007172456,0.01392989,0.003368709,0.009276932,0.01264522],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01643134,"about_ca_system_score_gemma":0.0603356,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.05656935,"about_ca_topic_score_gemma":0.1193256,"domain_scores_codex":[0.9729725,0.01543883,0.002641585,0.001514401,0.005087646,0.002345015],"domain_scores_gemma":[0.887235,0.03548014,0.006948881,0.003889061,0.02441066,0.0420362],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008072436,0.0001649685,0.001588732,0.001851779,0.00009651277,0.0001143562,0.0003253949,0.0000912561,0.000158321,0.01181186,0.7539699,0.2290196],"study_design_scores_gemma":[0.001980751,0.0002129662,0.001740358,0.006329899,0.0001299365,0.0001570825,0.0006592686,0.0001582753,0.00009853581,0.01845478,0.9699836,0.00009455676],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.0006036325,0.04440042,0.0005270736,0.9325104,0.01038471,0.0003710916,0.0004538487,0.00008603444,0.01066286],"genre_scores_gemma":[0.01686911,0.06058858,0.01030426,0.8525995,0.03284695,0.002685098,0.001182806,0.0002737685,0.02264987],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.05656935,"threshold_uncertainty_score":0.2982382,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4403622172","doi":"10.58931/cht.2023.2340","title":"Monoclonal gammopathy of clinical and undetermined significance","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Monoclonal gammopathy; Paraproteinemias; Medicine; Monoclonal; Immunology; Monoclonal antibody; Antibody","authors":[{"name":"Alissa Visram","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07689407381640198,"gpt":0.3801003601665178,"spread":0.3032062863501158,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000316659,0.0003473927,0.0004101463,0.001416853,0.0005986454,0.0004791698,0.0003247165,0.0006564958,0.006867305],"category_scores_gemma":[0.00131088,0.00007208889,0.0002308415,0.001075096,0.0003309181,0.0002971712,0.0002873103,0.0003744928,0.001236447],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004079997,"about_ca_system_score_gemma":0.0007513916,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00728994,"about_ca_topic_score_gemma":0.01034649,"domain_scores_codex":[0.9997144,0.00003606754,0.00002848185,0.00003197598,0.000109788,0.00007921781],"domain_scores_gemma":[0.9995733,0.000050202,0.00009809755,0.00002011677,0.0001486086,0.0001097884],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001273901,0.00035501,0.6204309,0.001042141,0.0001456526,0.09005702,0.0005815402,0.0002202819,0.02145666,0.006153546,0.05379094,0.2044924],"study_design_scores_gemma":[0.0001187664,0.0004793068,0.6617682,0.0008054054,0.000187491,0.1779433,0.0003501758,0.000526946,0.004222611,0.002053239,0.1514965,0.00004802528],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.6210462,0.0570719,0.002761295,0.006345575,0.0008628475,0.0008138738,0.004605383,0.0004252383,0.3060676],"genre_scores_gemma":[0.9678248,0.007412965,0.001339061,0.001262077,0.0003486071,0.00005838347,0.001938574,0.00001824659,0.01979716],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.00728994,"threshold_uncertainty_score":0.02297348,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417129987","doi":"10.58931/cht.2025.4379","title":"Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor","year":2025,"lang":"","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Surrey Place Centre","funders":"","keywords":"Multiple myeloma; Toxicity; Chimeric antigen receptor; Drug; Disease; Monoclonal antibody; Adverse effect; Bortezomib","authors":[{"name":"Jesse Shustik","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02014622794762031,"gpt":0.2911424927427976,"spread":0.2709962647951772,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001130107,0.0002847402,0.0006140902,0.000405604,0.0002939221,0.0007374335,0.000257004,0.0002877105,0.001297232],"category_scores_gemma":[0.0005726784,0.000102035,0.0004227589,0.0003510035,0.0003823447,0.0006808923,0.0004876897,0.001183417,0.000231365],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001141281,"about_ca_system_score_gemma":0.0006372177,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000680807,"about_ca_topic_score_gemma":0.004094944,"domain_scores_codex":[0.9997444,0.00008449085,0.00002106968,0.00002978555,0.00007875818,0.00004144431],"domain_scores_gemma":[0.9996653,0.0001139019,0.00006652274,0.00001483782,0.00007737162,0.0000621922],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008592179,0.000183929,0.003777164,0.001307071,0.000177504,0.001721471,0.000186338,0.001327854,0.02413079,0.008040348,0.01858008,0.9397082],"study_design_scores_gemma":[0.0007374305,0.004936819,0.0340021,0.001183123,0.0005189372,0.02764147,0.0003097478,0.003243293,0.02735601,0.01117344,0.8888187,0.00007898232],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1157182,0.8238588,0.005140594,0.02664038,0.001053055,0.00006556364,0.000150108,0.0001736391,0.02719957],"genre_scores_gemma":[0.5034838,0.46349,0.006931218,0.01057784,0.004446038,0.00007740529,0.0003443224,0.00008263248,0.01056661],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001297232,"threshold_uncertainty_score":0.008280575,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384199598","doi":"10.58931/cht.2023.2234","title":"Acute myeloid leukemia induction in the age of novel therapeutic agents","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Medicine; Cytarabine; Idarubicin; Myeloid leukemia; Oncology; Internal medicine; Myeloid; Anthracycline; Daunorubicin; Transplantation; Disease; Leukemia; Intensive care medicine; Cancer","authors":[{"name":"Nicholas Forward","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05621292049936643,"gpt":0.3244565945704068,"spread":0.2682436740710404,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005655907,0.00032813,0.0006419674,0.000243715,0.0002440922,0.000875743,0.0004691753,0.0006372811,0.004042942],"category_scores_gemma":[0.0005907037,0.0001375434,0.0004532099,0.0002122641,0.0002907543,0.0009164874,0.0008813038,0.002126928,0.00186924],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005576828,"about_ca_system_score_gemma":0.0004527934,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001726555,"about_ca_topic_score_gemma":0.0005114711,"domain_scores_codex":[0.9997289,0.00006439049,0.00002204012,0.00004834565,0.00007771607,0.00005863497],"domain_scores_gemma":[0.9997644,0.00004960107,0.00005995974,0.00002163858,0.00005275385,0.00005169094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00192012,0.001169131,0.003629908,0.002564283,0.0001558979,0.001351502,0.0003241794,0.001398008,0.103707,0.03111441,0.05727839,0.7953873],"study_design_scores_gemma":[0.0004852752,0.002989836,0.004266229,0.0007518988,0.0001532984,0.003779159,0.00009104885,0.001087813,0.0365506,0.008438924,0.9413655,0.00004040469],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.166047,0.6304675,0.02647036,0.03339401,0.00767771,0.0008472179,0.001124338,0.001106919,0.132865],"genre_scores_gemma":[0.577045,0.3295535,0.01806865,0.01872171,0.004903642,0.0008968302,0.00194605,0.0001454494,0.04871927],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004042942,"threshold_uncertainty_score":0.01352501,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4411729473","doi":"10.58931/cht.2025.4s0469","title":"Advancing BTK Inhibition: Non‑Covalent Bruton Tyrosine Kinase Inhibitors and Their Emerging Role in Canadian Practice","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"Hebrew University of Jerusalem","keywords":"Bruton's tyrosine kinase; Tyrosine kinase; Covalent bond; Chemistry; Biochemistry; Signal transduction","authors":[{"name":"Jonathan Isenberg","is_ca":true},{"name":"Alina S. Gerrie","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.005584451970101021,"gpt":0.2758105374282682,"spread":0.2702260854581672,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002792784,0.0004973882,0.0005453413,0.001365364,0.001181914,0.002528484,0.001237698,0.001741537,0.0128689],"category_scores_gemma":[0.003757184,0.0001914497,0.0003717728,0.001863864,0.002115503,0.001677907,0.0014038,0.002985878,0.001720048],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01521649,"about_ca_system_score_gemma":0.02471162,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.236955,"about_ca_topic_score_gemma":0.428086,"domain_scores_codex":[0.9988441,0.0002096105,0.00006988873,0.00014056,0.0005379274,0.0001977377],"domain_scores_gemma":[0.9968347,0.0004455521,0.000342926,0.00007745872,0.001428837,0.0008705169],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005935734,0.0001846141,0.002182103,0.001746778,0.00007156622,0.000641827,0.0003908753,0.0006800143,0.004141327,0.02812381,0.1411533,0.8200901],"study_design_scores_gemma":[0.0001946484,0.0002404488,0.002577016,0.001013921,0.00004879301,0.0007934179,0.000192545,0.0003216168,0.001150377,0.004725205,0.9887077,0.00003439388],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.009497758,0.7942796,0.002882314,0.1278362,0.003732305,0.0001027823,0.0004762743,0.0001729278,0.06101986],"genre_scores_gemma":[0.09791652,0.8378612,0.006458947,0.03142668,0.002744126,0.00006701578,0.0006072242,0.00009296875,0.02282524],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.763045,"threshold_uncertainty_score":0.4711516,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4403622162","doi":"10.58931/cht.2023.2342","title":"Chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma: The evolving Canadian landscape","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Gilead Sciences; Sanofi","keywords":"Chimeric antigen receptor; Multiple myeloma; Antigen; Immunology; Receptor; Medicine; Cancer research; Virology; Biology; Immunotherapy; Internal medicine; Immune system","authors":[{"name":"Sita Bhella","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02781133904866197,"gpt":0.2724164986273658,"spread":0.2446051595787038,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006274331,0.0004954903,0.0007744834,0.002090832,0.002220613,0.003055415,0.001586562,0.002205087,0.01097903],"category_scores_gemma":[0.006724352,0.0002128593,0.0004472387,0.004111651,0.003496171,0.002300664,0.001845725,0.004040285,0.00163429],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02738625,"about_ca_system_score_gemma":0.04924434,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.4278964,"about_ca_topic_score_gemma":0.6190782,"domain_scores_codex":[0.9979782,0.0003780237,0.0001201688,0.0002334293,0.0009601635,0.0003300085],"domain_scores_gemma":[0.9927597,0.001267202,0.0003740377,0.0001056845,0.004038124,0.001455278],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006129391,0.0002241094,0.002508467,0.002159182,0.00009710116,0.000458862,0.0003851192,0.001236331,0.001964833,0.05551614,0.1888339,0.7460031],"study_design_scores_gemma":[0.0001674587,0.0002836081,0.00308611,0.001484023,0.0001126169,0.0006127977,0.0004826794,0.0006002003,0.000752785,0.006602238,0.9857686,0.00004695047],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00542839,0.7127001,0.001614597,0.2474798,0.003493699,0.0000477627,0.0003444029,0.0001244319,0.02876692],"genre_scores_gemma":[0.06279214,0.8873407,0.002804045,0.03378167,0.003504518,0.00006161958,0.0003840411,0.00008693981,0.00924418],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.5721036,"threshold_uncertainty_score":0.8508115,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4403622138","doi":"10.58931/cht.2024.3149","title":"Systemic Mastocytosis: Diagnosis and Management in 2024","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"St. Michael's Hospital","funders":"University of Toronto","keywords":"Systemic mastocytosis; Medicine; Dermatology; Intensive care medicine; Pathology; Bone marrow","authors":[{"name":"Stephanie J. Lee","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009494273569585645,"gpt":0.2162652633113822,"spread":0.2067709897417966,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002688135,0.0004006092,0.0004622401,0.0007436596,0.0005731548,0.000641887,0.0004041539,0.001032893,0.001562505],"category_scores_gemma":[0.0007467986,0.0001488779,0.0001881033,0.0006229803,0.0003254693,0.0005404769,0.0005571943,0.00112686,0.0005812232],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008858514,"about_ca_system_score_gemma":0.001354528,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00583652,"about_ca_topic_score_gemma":0.008524476,"domain_scores_codex":[0.9998181,0.00002612692,0.00002648814,0.00001956995,0.00006469034,0.00004499125],"domain_scores_gemma":[0.999846,0.00002494245,0.00002840888,0.000003475267,0.00003963122,0.00005749281],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003097533,0.0001791728,0.06706282,0.001431217,0.00006978558,0.3096727,0.001282693,0.0007436526,0.008706377,0.006232097,0.08430579,0.5200041],"study_design_scores_gemma":[0.00005404132,0.0002208727,0.03621746,0.003198756,0.0000768586,0.7115925,0.001542764,0.0008382229,0.001216163,0.004976576,0.2400111,0.00005477755],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1074269,0.7614419,0.01113127,0.0357974,0.003093426,0.0002497338,0.0004839716,0.0002336563,0.08014169],"genre_scores_gemma":[0.537763,0.4147281,0.01202515,0.01417406,0.007575566,0.0001047091,0.001132235,0.0000451365,0.01245203],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00583652,"threshold_uncertainty_score":0.01160508,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384134175","doi":"10.58931/cht.2023.2233","title":"Evolving role of novel therapies in myeloma: T-cell engagers and antibody-drug conjugates","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Dalhousie University","funders":"","keywords":"Lenalidomide; Medicine; Daratumumab; Carfilzomib; Multiple myeloma; Pomalidomide; Thalidomide; Bortezomib; Internal medicine; Population; Oncology; Ixazomib; Proteasome inhibitor; Immunology","authors":[{"name":"Alfredo De La Torre","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01769668187226716,"gpt":0.2869579039078653,"spread":0.2692612220355982,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00247727,0.0006052554,0.0009652274,0.000784185,0.0003491745,0.002344275,0.000979187,0.002247961,0.005667476],"category_scores_gemma":[0.00179751,0.0002620276,0.000667812,0.0005725679,0.00112696,0.003925276,0.001594882,0.00393489,0.002266664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001119636,"about_ca_system_score_gemma":0.0007821214,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003600476,"about_ca_topic_score_gemma":0.0009241236,"domain_scores_codex":[0.9993198,0.0002271921,0.00003859873,0.0001052356,0.000205058,0.0001041237],"domain_scores_gemma":[0.9989787,0.0004956528,0.0001053459,0.00003362153,0.0002001971,0.0001864824],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003990177,0.0004601858,0.001005173,0.002887499,0.0001366104,0.0005674691,0.0002457433,0.002064353,0.01702726,0.05293012,0.07753044,0.8447461],"study_design_scores_gemma":[0.0001682904,0.001494846,0.0007660459,0.000830197,0.0000681295,0.001175851,0.0001613475,0.002224685,0.006595267,0.01900136,0.9674664,0.00004759772],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.007707823,0.9466989,0.006293318,0.02389632,0.002774315,0.00007477179,0.0002014046,0.0002315629,0.01212155],"genre_scores_gemma":[0.06520247,0.8844184,0.01164881,0.01957918,0.00459625,0.0002411653,0.0005153649,0.00008084993,0.01371756],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005667476,"threshold_uncertainty_score":0.01895958,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384461377","doi":"10.58931/cht.2022.1s1227","title":"Updates in the treatment of mantle cell lymphoma: A Canadian expert framework","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"BeiGene; Royal College of Physicians and Surgeons of Canada; Bristol-Myers Squibb; Canadian Hematology Society; AstraZeneca; Celgene; Gilead Sciences","keywords":"Mantle cell lymphoma; Blastoid; IGHV@; Lymphoma; Bone marrow; Cancer research; Lymph node; Medicine; Follicular lymphoma; Biology; Oncology; Internal medicine; Chronic lymphocytic leukemia; Leukemia","authors":[{"name":"Diego Villa","is_ca":false},{"name":"Roopesh Kansara","is_ca":false},{"name":"Christopher Lemieux","is_ca":false},{"name":"John Kuruvilla","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01419186452329993,"gpt":0.2532317796375717,"spread":0.2390399151142718,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01088402,0.001112167,0.0016411,0.003272237,0.002246103,0.004014762,0.004761681,0.006579055,0.01508451],"category_scores_gemma":[0.01712519,0.0004820211,0.001847196,0.003104723,0.002217724,0.00359323,0.003233995,0.01050298,0.004850744],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02365291,"about_ca_system_score_gemma":0.04926656,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.2749673,"about_ca_topic_score_gemma":0.4676826,"domain_scores_codex":[0.9949826,0.0007919286,0.0005608861,0.0003983159,0.002489877,0.000776341],"domain_scores_gemma":[0.9714475,0.00295448,0.001244321,0.000336595,0.01911806,0.004898987],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000108474,0.00007579744,0.0004021544,0.00182502,0.00004719463,0.000204937,0.0001750409,0.0005003273,0.000415248,0.004283756,0.5869648,0.4049972],"study_design_scores_gemma":[0.00003142539,0.00003547263,0.0004397933,0.0035189,0.00004039174,0.000199948,0.00007561492,0.00008813637,0.00006167027,0.001048931,0.9944384,0.00002133582],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"methods","genre_scores_codex":[0.0005941337,0.6316273,0.001499341,0.3180185,0.01651538,0.0001569689,0.0005991877,0.0002577532,0.03073151],"genre_scores_gemma":[0.008211575,0.8169724,0.0100278,0.123779,0.01940059,0.0001796058,0.001939414,0.0001896162,0.01929999],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.7250327,"threshold_uncertainty_score":0.5467335,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384463921","doi":"10.58931/cht.2022.1214","title":"Chimeric antigen receptor T-cell therapy for relapsed and refractory large B-cell lymphoma","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Chemoimmunotherapy; Medicine; Rituximab; Lymphoma; Vincristine; Internal medicine; Oncology; Cyclophosphamide; Chemotherapy; Refractory (planetary science); Salvage therapy; Prednisone; CHOP; Autologous stem-cell transplantation","authors":[{"name":"Mahmoud Elsawy","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01717987800143865,"gpt":0.2704167497535929,"spread":0.2532368717521542,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002241557,0.0001821551,0.0003251642,0.0003049207,0.0003100327,0.0002597215,0.0003378236,0.0003632715,0.003961583],"category_scores_gemma":[0.0001815416,0.00004614732,0.0002617677,0.0002680657,0.000200213,0.0001769917,0.0001662436,0.0007097083,0.00105484],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001404091,"about_ca_system_score_gemma":0.0008051996,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01169506,"about_ca_topic_score_gemma":0.02899677,"domain_scores_codex":[0.9999274,0.00001317647,0.000002643061,0.000006006301,0.00002406357,0.00002667763],"domain_scores_gemma":[0.9999436,0.000006935352,0.000007136837,0.000004508428,0.00001124181,0.00002661367],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003648278,0.001522646,0.003442711,0.0005499033,0.0002045501,0.003685922,0.0001940738,0.001670385,0.03115266,0.003010413,0.06705559,0.883863],"study_design_scores_gemma":[0.01441991,0.0215555,0.08560919,0.0005322147,0.000472538,0.02482265,0.0003701466,0.01084647,0.02815623,0.00473971,0.8083688,0.0001066268],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.6749475,0.1622351,0.009782253,0.013225,0.002444444,0.000964988,0.0009816404,0.001637468,0.1337817],"genre_scores_gemma":[0.9499873,0.02617445,0.002777511,0.002986321,0.0004054478,0.0001626921,0.001077275,0.00005523624,0.0163738],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.01169506,"threshold_uncertainty_score":0.02325398,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4403622166","doi":"10.58931/cht.2024.3252","title":"Therapy for Myelodysplastic Syndromes Beyond the Front Line in 2024 in Canada","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Sunnybrook Health Science Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Sunnybrook Research Institute; Leukemia and Lymphoma Society of Canada","keywords":"Front line; Myelodysplastic syndromes; Medicine; History; Internal medicine; Archaeology","authors":[{"name":"Rena Buckstein","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01881398111461455,"gpt":0.2800930793534141,"spread":0.2612790982387996,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007115317,0.0003004788,0.0003748004,0.0008184295,0.001199382,0.001191902,0.0007590143,0.0006845588,0.01248796],"category_scores_gemma":[0.001378554,0.0001462366,0.0004754461,0.001604771,0.0003865092,0.0003919246,0.0005762453,0.001416401,0.00118459],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02591161,"about_ca_system_score_gemma":0.08620136,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9100958,"about_ca_topic_score_gemma":0.9712414,"domain_scores_codex":[0.9995356,0.00004578878,0.00003396573,0.00003458514,0.0002112814,0.0001388423],"domain_scores_gemma":[0.9986903,0.00006273499,0.00009774794,0.00001317511,0.000642409,0.0004936546],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008305878,0.0001513013,0.01067479,0.003133193,0.0001597252,0.001645489,0.0004470077,0.0009468669,0.0029706,0.014487,0.3906224,0.573931],"study_design_scores_gemma":[0.0002772681,0.0001592761,0.02100178,0.002260876,0.0001543268,0.001022266,0.0002571084,0.0002773734,0.0006273938,0.0009637439,0.9729633,0.00003536915],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0433624,0.6548511,0.00182,0.1153963,0.005681631,0.0004277538,0.01494442,0.000274805,0.1632416],"genre_scores_gemma":[0.2289228,0.6382701,0.007632174,0.0343937,0.0015224,0.0002262588,0.01534001,0.0001240677,0.0735685],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.08990419,"threshold_uncertainty_score":0.1880028,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4403622134","doi":"10.58931/cht.2023.2341","title":"Frontline treatment of aggressive B-cell lymphoma","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University","funders":"","keywords":"Lymphoma; Aggressive lymphoma; B-cell lymphoma; Medicine; Cancer research; Internal medicine; Rituximab","authors":[{"name":"Shannon Murphy","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01861575547947897,"gpt":0.2644674569887634,"spread":0.2458517015092844,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001401877,0.0003213857,0.000442458,0.0005509722,0.0002374466,0.0005317828,0.0004574642,0.0004835581,0.02486348],"category_scores_gemma":[0.0003185354,0.00005505692,0.0004194313,0.000335498,0.0001053872,0.0003929266,0.0002835412,0.00100377,0.01445873],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005592776,"about_ca_system_score_gemma":0.0002885118,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009711476,"about_ca_topic_score_gemma":0.002840151,"domain_scores_codex":[0.9998778,0.00001972653,0.000008458859,0.000014902,0.00004870933,0.00003033391],"domain_scores_gemma":[0.9998764,0.00001773126,0.00002015018,0.000006681131,0.00003398447,0.00004504066],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006678686,0.0002349637,0.001326961,0.001156214,0.0001188094,0.001170086,0.00004820436,0.0004469922,0.005100159,0.001634382,0.2184277,0.7696676],"study_design_scores_gemma":[0.0003279755,0.0004358607,0.005983075,0.0008711335,0.000102545,0.004373264,0.00004459665,0.0003859285,0.002668134,0.001957116,0.9828342,0.00001622367],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.05753309,0.4806604,0.01903048,0.01810349,0.009415156,0.0007582056,0.007344045,0.002506073,0.4046491],"genre_scores_gemma":[0.3764472,0.3203306,0.02010785,0.02407654,0.0105684,0.0008094823,0.02675505,0.000605115,0.2202998],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02486348,"threshold_uncertainty_score":0.08317661,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417130011","doi":"10.58931/cht.2025.4380","title":"Rational Use of Immunoglobulin in Adult Patients with Secondary Hypogammaglobulinemia in the Setting of Hematologic Malignancy: A Canadian Perspective","year":2025,"lang":"","type":"article","venue":"Canadian Hematology Today","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Canadian Blood Services; University of Calgary; Saskatchewan Health; Saskatchewan Health Authority","funders":"","keywords":"Hypogammaglobulinemia; Chronic lymphocytic leukemia; Antibody; Context (archaeology); Rituximab; Multiple myeloma; Lymphoma; Immunoglobulin G; Acute lymphocytic leukemia","authors":[{"name":"Oksana Prokopchuk‐Gauk","is_ca":true},{"name":"Kathryn E. Webert","is_ca":true},{"name":"Jennifer Grossman","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.005257888975597179,"gpt":0.2059298217133525,"spread":0.2006719327377553,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001290252,0.0003693767,0.0006344331,0.001303815,0.001282726,0.001545534,0.001326968,0.001728076,0.004159515],"category_scores_gemma":[0.004006964,0.000173826,0.0005145003,0.001025224,0.0007646373,0.0009820267,0.0009224824,0.003105585,0.0007628833],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.009853782,"about_ca_system_score_gemma":0.02288901,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.3055292,"about_ca_topic_score_gemma":0.4220299,"domain_scores_codex":[0.9992791,0.0001532503,0.0001030967,0.00008152074,0.0002400389,0.0001431013],"domain_scores_gemma":[0.9964157,0.0002522652,0.0002293108,0.00003565496,0.00190162,0.001165342],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006633854,0.000525522,0.07804865,0.001694489,0.0001672413,0.01117302,0.001174956,0.000961392,0.00236094,0.0123696,0.2764831,0.6143777],"study_design_scores_gemma":[0.000452781,0.0006689033,0.140323,0.01085481,0.0004531792,0.01997255,0.003656535,0.001861882,0.0008262966,0.007396808,0.8133283,0.0002048833],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.03729185,0.4433756,0.005208815,0.4355533,0.004722832,0.0002470674,0.0007431777,0.0002543427,0.07260307],"genre_scores_gemma":[0.3556412,0.4913704,0.01741587,0.1095454,0.009568574,0.0001827541,0.001133936,0.0001510051,0.0149908],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6944708,"threshold_uncertainty_score":0.6075016,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384134134","doi":"10.58931/cht.2023.2231","title":"Coronavirus disease (COVID-19) in patients with hematologic malignancy","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Pandemic; Medicine; Coronavirus; Malignancy; Disease; Hematologic malignancy; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Outbreak; Virology; Public health; Intensive care medicine; Internal medicine; Infectious disease (medical specialty); Pathology","authors":[{"name":"Inna Y. Gong","is_ca":true},{"name":"Lisa K. Hicks","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1265880436774669,"gpt":0.3923899728283335,"spread":0.2658019291508665,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002823464,0.0001314077,0.0002024263,0.0006639213,0.001031031,0.000574171,0.0001797387,0.0004127434,0.003018906],"category_scores_gemma":[0.001575812,0.00005956976,0.0001997847,0.001195046,0.0002923495,0.0003058798,0.0006042243,0.0009544943,0.0002215505],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002163662,"about_ca_system_score_gemma":0.003925461,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1394636,"about_ca_topic_score_gemma":0.217967,"domain_scores_codex":[0.9996258,0.00006443613,0.0000278195,0.00002814319,0.0001412108,0.0001126119],"domain_scores_gemma":[0.9996237,0.0000522161,0.00009487588,0.000004955406,0.00008567276,0.0001386516],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001967679,0.000100428,0.7870728,0.0007008408,0.00008431158,0.003717224,0.001305576,0.0001487305,0.0005929571,0.002987753,0.04524719,0.1578455],"study_design_scores_gemma":[0.00002907715,0.0002090128,0.8418587,0.003183592,0.0001964501,0.01111371,0.004830929,0.0001932042,0.0002181592,0.002342782,0.1357788,0.00004564874],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4358383,0.3068522,0.0008444682,0.07369214,0.001469226,0.000257018,0.003220351,0.00008688525,0.1777395],"genre_scores_gemma":[0.882543,0.1040523,0.0007497329,0.007044507,0.00116066,0.00003909707,0.001064648,0.000009055742,0.003336993],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8605364,"threshold_uncertainty_score":0.2773037,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384274089","doi":"10.58931/cht.2022.1316","title":"Moving beyond chemotherapy in the management of follicular lymphoma","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Rituximab; Medicine; Regimen; Follicular lymphoma; Bendamustine; Internal medicine; Oncology; Chemotherapy; Lymphoma; Chemotherapy regimen; Induction chemotherapy; Surgery","authors":[{"name":"Robert Kridel","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.00916739963115653,"gpt":0.2373039445087466,"spread":0.2281365448775901,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008162289,0.0002560482,0.0004074243,0.0005864394,0.0007480619,0.001050203,0.0006701787,0.001095954,0.004971823],"category_scores_gemma":[0.001743031,0.00006377706,0.000330605,0.0005217108,0.0006864874,0.0008065512,0.0007512934,0.00221966,0.001097375],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00670466,"about_ca_system_score_gemma":0.004663064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.05433591,"about_ca_topic_score_gemma":0.1702577,"domain_scores_codex":[0.9995515,0.0001035643,0.00002779664,0.00004549691,0.0001746097,0.00009711932],"domain_scores_gemma":[0.999087,0.0002077717,0.0001089023,0.00002365763,0.0002649096,0.0003078208],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004675289,0.0001601022,0.002842247,0.001158617,0.00006805782,0.0009127515,0.0002709874,0.0009762318,0.001756555,0.007621806,0.1129276,0.8708375],"study_design_scores_gemma":[0.0002544219,0.0004886417,0.007681539,0.002394446,0.00007476189,0.002131353,0.0002260205,0.0003904935,0.0004857911,0.004814125,0.98103,0.00002835826],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.02212323,0.6869181,0.003494979,0.1642617,0.005193013,0.0002191663,0.0002504527,0.0001437251,0.1173957],"genre_scores_gemma":[0.2432606,0.589216,0.01168665,0.1057173,0.01313979,0.0002012292,0.000732888,0.0001464578,0.03589914],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.05433591,"threshold_uncertainty_score":0.1080393,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4403622135","doi":"10.58931/cht.2024.3148","title":"Follicular Non-Hodgkin Lymphoma: First Relapse and Beyond","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Nova Scotia Health Authority","funders":"Acadia University","keywords":"Follicular lymphoma; Follicular phase; Lymphoma; Medicine; Oncology; Hodgkin lymphoma; Internal medicine","authors":[{"name":"Mary‐Margaret Keating","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007170227836454627,"gpt":0.2335209303813079,"spread":0.2263507025448533,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006792998,0.0003002629,0.000932214,0.0008181261,0.0005244421,0.001185934,0.0006517892,0.0007569827,0.004913237],"category_scores_gemma":[0.001522177,0.0001178693,0.0005956247,0.001155967,0.0005365509,0.0007065716,0.0004443518,0.001062435,0.0008624998],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005025566,"about_ca_system_score_gemma":0.008641175,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.14216,"about_ca_topic_score_gemma":0.2715472,"domain_scores_codex":[0.9996058,0.0000510349,0.0000366336,0.00003788189,0.0001799608,0.00008873176],"domain_scores_gemma":[0.9992359,0.0001429345,0.0001131952,0.00002295953,0.0003757915,0.0001092633],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003982678,0.00006413453,0.004964597,0.01295127,0.0001316617,0.001985528,0.0004661891,0.0002531877,0.001650245,0.007464917,0.09832241,0.8713477],"study_design_scores_gemma":[0.0000915786,0.0001481881,0.01051064,0.009067825,0.0002976653,0.008797337,0.0004050115,0.0001289007,0.0007808099,0.002775784,0.9669549,0.00004112651],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.004534261,0.9651939,0.0003037639,0.005086141,0.0005459248,0.00005390299,0.0004149548,0.00004379333,0.02382341],"genre_scores_gemma":[0.06910704,0.9133821,0.001046071,0.005555557,0.0009681369,0.00003942917,0.0008822758,0.00002106157,0.008998432],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.14216,"threshold_uncertainty_score":0.2826651,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4403602456","doi":"10.58931/cht.2023.2339","title":"The role of FDG-PET scanning and PET-adapted therapy in the primary treatment of Hodgkin lymphoma: A primer for clinicians","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Primer (cosmetics); Pet imaging; PET-CT; Medicine; Hodgkin lymphoma; Lymphoma; Medical physics; Nuclear medicine; Positron emission tomography; Radiology; Internal medicine; Chemistry","authors":[{"name":"Michael Crump","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0240633307411725,"gpt":0.2874105923960588,"spread":0.2633472616548863,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01007272,0.001012778,0.001776432,0.002729382,0.001080389,0.00483831,0.002075433,0.006008358,0.001720292],"category_scores_gemma":[0.01456649,0.0006230539,0.0007311713,0.001684272,0.005507249,0.008463696,0.002081467,0.01727887,0.001508258],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003883613,"about_ca_system_score_gemma":0.004532763,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00584774,"about_ca_topic_score_gemma":0.009011217,"domain_scores_codex":[0.9973648,0.001095957,0.0004263585,0.0002304467,0.0007194859,0.0001629931],"domain_scores_gemma":[0.9902703,0.005557439,0.0005527649,0.0002913001,0.00242424,0.0009040927],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001565101,0.0001321496,0.003168617,0.002678787,0.00006000443,0.002771317,0.001440351,0.0005701429,0.001744694,0.02338335,0.1980137,0.7658805],"study_design_scores_gemma":[0.00006122498,0.0002124222,0.002742604,0.008834501,0.00007662134,0.01249821,0.002023636,0.0007765724,0.0005891625,0.0385297,0.9335108,0.0001444306],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007577262,0.7713382,0.007810722,0.2073901,0.006253132,0.00004608488,0.0000387622,0.0001294209,0.006235936],"genre_scores_gemma":[0.01321413,0.8838865,0.02032626,0.05798142,0.02182291,0.0001241234,0.00007654726,0.00008323156,0.00248491],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01007272,"threshold_uncertainty_score":0.05327028,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384463912","doi":"10.58931/cht.2022.1211","title":"Immunotherapy in Hodgkin lymphoma","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Brentuximab vedotin; Medicine; Pembrolizumab; Nivolumab; Oncology; Internal medicine; Lymphoma; Clinical trial; Malignancy; Immunotherapy; Chemotherapy; Cancer; Hodgkin lymphoma","authors":[{"name":"John Kuruvilla","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01106378067861947,"gpt":0.2438885588094986,"spread":0.2328247781308792,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000572279,0.0002224318,0.0003708008,0.0005046115,0.0003625987,0.0005476145,0.0002637548,0.0009102967,0.003560296],"category_scores_gemma":[0.0005606312,0.000101951,0.000288993,0.000417173,0.0003843806,0.0004753386,0.0004307221,0.001329325,0.001059143],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001298581,"about_ca_system_score_gemma":0.001260909,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001772045,"about_ca_topic_score_gemma":0.003548789,"domain_scores_codex":[0.999788,0.00006962119,0.00001774366,0.00001901879,0.00005283047,0.00005284322],"domain_scores_gemma":[0.999806,0.00006855914,0.0000288409,0.00001069574,0.00003978121,0.00004611335],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003761641,0.0003803119,0.003308971,0.002200782,0.00006749212,0.001441325,0.0001632349,0.0008024838,0.006601662,0.01425698,0.08513162,0.8852691],"study_design_scores_gemma":[0.0003306484,0.0007597994,0.005585376,0.001355798,0.0000651371,0.005872759,0.0001099399,0.0003767494,0.002283381,0.008354331,0.9748872,0.00001898274],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01355475,0.9270723,0.00104142,0.0195792,0.003316354,0.0000758294,0.0001092488,0.00007461391,0.03517641],"genre_scores_gemma":[0.1393902,0.8137335,0.002432073,0.01926698,0.008283754,0.0001971953,0.0003789269,0.00002009107,0.01629729],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003560296,"threshold_uncertainty_score":0.01191038,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384383301","doi":"10.58931/cht.2023.2121","title":"Frontline management of transplant-ineligible newly diagnosed multiple myeloma (TINDMM) in Canada","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Northern British Columbia; University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Multiple myeloma; Malignancy; Hematologic malignancy; Anemia; Bone marrow transplant; Bone marrow; Internal medicine; Pediatrics; Bone marrow transplantation","authors":[{"name":"Christopher P. Venner","is_ca":true},{"name":"Julia Varghese","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0207331733756894,"gpt":0.2643517528212895,"spread":0.2436185794456001,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002875142,0.0001417931,0.0002295977,0.0006078662,0.003817632,0.00110645,0.0009590846,0.0005028316,0.009027269],"category_scores_gemma":[0.001276111,0.0001105652,0.0002612157,0.00113726,0.000459595,0.0003445714,0.0009967231,0.001229256,0.0005482328],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.03203433,"about_ca_system_score_gemma":0.06836136,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9561937,"about_ca_topic_score_gemma":0.9883122,"domain_scores_codex":[0.999535,0.00002871033,0.00002069746,0.00003892012,0.0001509471,0.0002257779],"domain_scores_gemma":[0.9980578,0.00004231728,0.0001526515,0.00001078737,0.0004290454,0.001307449],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"observational","study_design_scores_codex":[0.0005897513,0.0005975061,0.3342187,0.0008410186,0.0001220412,0.009495721,0.002513271,0.0009024722,0.002665413,0.008562179,0.3392536,0.3002383],"study_design_scores_gemma":[0.0003539816,0.0003165104,0.5082864,0.002476117,0.0001596772,0.008245236,0.008152883,0.002068866,0.0008237454,0.003227492,0.4657707,0.0001184516],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4865159,0.04908264,0.002081804,0.2027044,0.002636962,0.0008321368,0.006687624,0.0003283548,0.2491302],"genre_scores_gemma":[0.8975543,0.02873017,0.00442653,0.03605123,0.0006135769,0.000114357,0.002880174,0.00009126645,0.02953825],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04380631,"threshold_uncertainty_score":0.2324263,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4409993751","doi":"10.58931/cht.2025.4163","title":"Richter Transformation in the Canadian Landscape: Clinical Perspectives and Emerging Trends","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"BC Cancer Agency; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Transformation (genetics); Geography; Biology","authors":[{"name":"Jean‐Nicolas Champagne","is_ca":true},{"name":"Alina S. Gerrie","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01575898755890943,"gpt":0.3218831674849407,"spread":0.3061241799260313,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001619874,0.0005058359,0.0006630086,0.002788572,0.002013012,0.003082379,0.001152345,0.0009892927,0.006507151],"category_scores_gemma":[0.004156451,0.0001625373,0.0003969641,0.005225256,0.00195979,0.001470185,0.001051718,0.002330504,0.0007998862],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02612343,"about_ca_system_score_gemma":0.06091411,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.7947922,"about_ca_topic_score_gemma":0.901904,"domain_scores_codex":[0.9989424,0.0001060312,0.0000638917,0.000116113,0.0005383408,0.000233082],"domain_scores_gemma":[0.9956803,0.0004136446,0.0003165064,0.00004113225,0.002788309,0.0007599466],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002143166,0.00007142575,0.01698231,0.004460672,0.000092862,0.001757896,0.00174068,0.0005383225,0.0009828964,0.02050103,0.1762822,0.7763753],"study_design_scores_gemma":[0.00002606926,0.00007137594,0.01493589,0.003922756,0.0001430222,0.003293716,0.002501138,0.0002951349,0.0003266609,0.003999778,0.9704047,0.00007975056],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.004434549,0.9185218,0.0005747147,0.05438587,0.001254694,0.00002312935,0.000448723,0.00006367196,0.0202928],"genre_scores_gemma":[0.03562075,0.950983,0.001331653,0.007813033,0.001427917,0.00001627748,0.00044985,0.0000283224,0.002329191],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.2052078,"threshold_uncertainty_score":0.4128326,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384383449","doi":"10.58931/cht.2022.1319","title":"Hereditary hematologic malignancies: a Canadian perspective","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"CEBPA; Germline; Genetic predisposition; Malignancy; Myeloid; Platelet disorder; Medicine; ETV6; Germline mutation; Cancer; GATA2; Genetics; Immunology; Biology; Mutation; Internal medicine; Gene; Disease; Chromosomal translocation; Platelet","authors":[{"name":"Amy M. Trottier","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01887377594990247,"gpt":0.2717560610194565,"spread":0.252882285069554,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001868854,0.0006495224,0.0007920593,0.003542177,0.006199652,0.002889308,0.001666949,0.00377451,0.01196153],"category_scores_gemma":[0.005221943,0.000375855,0.0004764139,0.004254476,0.003994962,0.002057604,0.001777384,0.006205757,0.001284567],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.04344147,"about_ca_system_score_gemma":0.07465124,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9171551,"about_ca_topic_score_gemma":0.9531489,"domain_scores_codex":[0.998396,0.0001559094,0.0001204911,0.0002232279,0.0007163225,0.0003880882],"domain_scores_gemma":[0.9914262,0.0007384398,0.0002715755,0.00009892425,0.004537301,0.002927531],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"observational","study_design_scores_codex":[0.0001068423,0.0001105309,0.01596122,0.001227279,0.00008075085,0.01624617,0.004053709,0.0004201664,0.0009730483,0.04837291,0.6993125,0.2131349],"study_design_scores_gemma":[0.00003141444,0.0000338283,0.0108088,0.002809886,0.00007524558,0.01513021,0.004655266,0.0001644891,0.0001057751,0.006383236,0.9597057,0.00009605718],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.006633739,0.3567982,0.0006634872,0.5467526,0.007807593,0.00003919406,0.0006258385,0.00007937006,0.08060009],"genre_scores_gemma":[0.08902159,0.758361,0.002367244,0.1221114,0.01086739,0.00003168459,0.0003923756,0.00007923238,0.01676815],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.08284485,"threshold_uncertainty_score":0.3151914,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384463905","doi":"10.58931/cht.2022.116","title":"Management of follicular lymphoma at first relapse","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba","funders":"","keywords":"Follicular lymphoma; Lymphoma; Medicine; Oncology; Internal medicine; Follicular phase; Disease","authors":[{"name":"Roopesh Kansara","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009802149988350896,"gpt":0.2230307044895199,"spread":0.2132285545011691,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003400533,0.0003398198,0.0006430206,0.0007223202,0.001061763,0.0007795774,0.000728514,0.0009535022,0.003153024],"category_scores_gemma":[0.001189996,0.00009929958,0.0004327579,0.0002329658,0.0002644622,0.0005505366,0.0006970539,0.001382325,0.00132167],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001671849,"about_ca_system_score_gemma":0.001014858,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005004799,"about_ca_topic_score_gemma":0.006573139,"domain_scores_codex":[0.9997019,0.00003583442,0.000023389,0.00003195385,0.00008502705,0.0001219225],"domain_scores_gemma":[0.9996418,0.0000316146,0.00004703613,0.00001615962,0.00008783944,0.0001755961],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008965175,0.0005144836,0.07693042,0.000896933,0.0001233373,0.1105191,0.001703959,0.001559044,0.02249117,0.003230432,0.08549517,0.6956395],"study_design_scores_gemma":[0.0002941798,0.002389788,0.1739301,0.003566034,0.0003168691,0.4566228,0.003295959,0.004608328,0.01502185,0.01047644,0.3292821,0.0001955039],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.5820926,0.17788,0.02774437,0.03036278,0.002521135,0.001083858,0.0009724403,0.001579469,0.1757634],"genre_scores_gemma":[0.9403492,0.02474737,0.006135768,0.006993745,0.002390822,0.0002193425,0.001015331,0.0001458829,0.0180025],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.005004799,"threshold_uncertainty_score":0.0121302,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4403597409","doi":"10.58931/cht.2022.1s1130","title":"Expert clinical framework report: Management of adverse events related to novel therapies for relapsed/refractory multiple myeloma (RRMM)","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Hôpital Charles-Le Moyne; Saskatchewan Cancer Agency; Saint John Regional Hospital; Capital District Health Authority; Southlake Regional Health Center; Alberta Cancer Foundation","funders":"","keywords":"Medicine; Multiple myeloma; Adverse effect; Lenalidomide; Intensive care medicine; Internal medicine","authors":[{"name":"Joanne Hewitt","is_ca":true},{"name":"Jennifer Daley-Morris","is_ca":true},{"name":"Judith James","is_ca":true},{"name":"Jonathan Stevens","is_ca":true},{"name":"Olivier Blaizel","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04678523042382879,"gpt":0.3616012315001819,"spread":0.3148160010763531,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01497313,0.001613531,0.00174698,0.001965457,0.002943089,0.006094508,0.004963564,0.01683827,0.08382501],"category_scores_gemma":[0.07509019,0.0005641359,0.00348105,0.00152164,0.001183579,0.002994403,0.007464737,0.008770652,0.0402136],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006027225,"about_ca_system_score_gemma":0.0286917,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006551209,"about_ca_topic_score_gemma":0.01143834,"domain_scores_codex":[0.9795642,0.008876161,0.003074077,0.001513209,0.005427966,0.001544419],"domain_scores_gemma":[0.9346356,0.01189213,0.009240194,0.001716961,0.02899344,0.01352173],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005932429,0.000075424,0.000392745,0.001149019,0.0000316501,0.0002371766,0.00006933312,0.0003381994,0.00007450711,0.001886707,0.8874315,0.1082544],"study_design_scores_gemma":[0.0002181388,0.0001172302,0.001006879,0.006667841,0.0000531741,0.000479449,0.0001240369,0.0004755242,0.00009757406,0.004890331,0.9858285,0.00004132732],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.0009221102,0.02618599,0.01256999,0.6290895,0.03515061,0.009049182,0.007776975,0.001611556,0.2776442],"genre_scores_gemma":[0.02499551,0.06986794,0.07196694,0.5453662,0.1028878,0.01391203,0.01895794,0.001088936,0.1509568],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.08382501,"threshold_uncertainty_score":0.2804226,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417129956","doi":"10.58931/cht.2025.4378","title":"Practical Management of Aggressive B-Cell Lymphomas with CD20×CD3 Bispecific Antibodies","year":2025,"lang":"","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Centre Hospitalier Universitaire de Québec; Royal College of Physicians and Surgeons of Canada; Université Laval","keywords":"Chimeric antigen receptor; Lymphoma; Cytokine release syndrome; Bispecific antibody; Blinatumomab; Immunotherapy; Aggressive lymphoma; Antibody","authors":[{"name":"Christopher Lemieux","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02374694346707146,"gpt":0.3227101856237286,"spread":0.2989632421566571,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006274491,0.0005405461,0.0006541811,0.0008480456,0.001027281,0.001032234,0.0007992313,0.001135064,0.002452562],"category_scores_gemma":[0.001185868,0.0001904851,0.0003828459,0.0006049423,0.0006466706,0.0007305716,0.0008537206,0.00253805,0.001007995],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002225754,"about_ca_system_score_gemma":0.003716894,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02280752,"about_ca_topic_score_gemma":0.05708534,"domain_scores_codex":[0.9996483,0.00006740518,0.00003554856,0.00002511686,0.000146862,0.00007683713],"domain_scores_gemma":[0.9996805,0.00005569283,0.00004761062,0.00001208244,0.0001059355,0.00009815899],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001935454,0.0001348266,0.005011838,0.001540389,0.00005810179,0.02801672,0.0005499453,0.001372153,0.009086231,0.006155546,0.1440448,0.803836],"study_design_scores_gemma":[0.0001616378,0.0003032489,0.009619334,0.001660837,0.0001337433,0.07048607,0.001050824,0.001279347,0.00537959,0.009809367,0.9000502,0.0000657612],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.03862166,0.666639,0.06616753,0.103793,0.00348578,0.0006987299,0.0004028018,0.001510859,0.1186807],"genre_scores_gemma":[0.2750604,0.5487254,0.09837367,0.04293943,0.007090997,0.0005581055,0.001010074,0.0002420088,0.02599985],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.02280752,"threshold_uncertainty_score":0.04534948,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4415701428","doi":"10.58931/cht.2025.4s0676","title":"Double-Exposed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Clinical Approach and Management","year":2025,"lang":"","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Calgary","funders":"","keywords":"Bruton's tyrosine kinase; Chronic lymphocytic leukemia; Lymphocytic infiltration; Ibrutinib; Immunotherapy; Clinical trial; Tyrosine kinase; Lymphoma; Refractory (planetary science)","authors":[{"name":"Robert Puckrin","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03811941451937106,"gpt":0.3164352858316126,"spread":0.2783158713122415,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005842853,0.000358279,0.0004808953,0.0007387653,0.0009361214,0.001401748,0.0007705531,0.0007518489,0.001368752],"category_scores_gemma":[0.001153457,0.0001029143,0.0002076351,0.0008132507,0.0007282645,0.0007851252,0.0009885818,0.001792482,0.0004339729],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003481562,"about_ca_system_score_gemma":0.009715772,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.05419912,"about_ca_topic_score_gemma":0.1471086,"domain_scores_codex":[0.9997069,0.00004934147,0.00003106555,0.0000282936,0.0001315554,0.00005269933],"domain_scores_gemma":[0.9995589,0.00003946421,0.00006192507,0.000008692117,0.0001857454,0.0001451999],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001138782,0.0000864041,0.01269779,0.002030041,0.00005869176,0.008870305,0.001138154,0.0008008663,0.005461525,0.00662127,0.09947122,0.8626497],"study_design_scores_gemma":[0.0001022868,0.0002684602,0.02322195,0.004498781,0.0001370747,0.04776864,0.00325774,0.0006025925,0.00144328,0.007652196,0.9109543,0.00009272376],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02369922,0.8241203,0.01495752,0.07061659,0.001986653,0.0003963045,0.000329109,0.0003211965,0.06357313],"genre_scores_gemma":[0.1696652,0.7678173,0.02549257,0.02072038,0.004118539,0.0002125311,0.0006761345,0.00007640698,0.01122099],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.05419912,"threshold_uncertainty_score":0.1077673,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384274087","doi":"10.58931/cht.2022.1317","title":"The evolving treatment landscape of higher-risk MDS","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Cytopenia; Myelodysplastic syndromes; Incidence (geometry); Myeloid leukemia; Medicine; Internal medicine; Oncology; Dysplasia; Leukemia; Bone marrow","authors":[{"name":"Mohamed Elemary","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01449227060263991,"gpt":0.2728385811535192,"spread":0.2583463105508793,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004427802,0.0002491798,0.0006887242,0.001045904,0.001189917,0.002858599,0.00104431,0.0014443,0.006688795],"category_scores_gemma":[0.00989983,0.0001666542,0.0004727706,0.0011458,0.001450106,0.001760473,0.001925532,0.003801087,0.001339623],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007047877,"about_ca_system_score_gemma":0.009355996,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0104866,"about_ca_topic_score_gemma":0.02854918,"domain_scores_codex":[0.9973956,0.0007520595,0.0002779533,0.0003522741,0.0008669146,0.0003551773],"domain_scores_gemma":[0.9941908,0.001227705,0.0006281249,0.0001140446,0.001748903,0.002090347],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003893163,0.0001550256,0.01060915,0.0009219683,0.00008217798,0.0008737262,0.00106631,0.001667179,0.001640642,0.03040974,0.1403212,0.8118636],"study_design_scores_gemma":[0.000120608,0.0004430443,0.01856888,0.002912247,0.00009886277,0.004138642,0.002174556,0.0008517641,0.0006929735,0.02297217,0.9469446,0.00008161942],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.0316834,0.3290873,0.003599719,0.5835587,0.00288467,0.00005566391,0.0006420633,0.0001717321,0.04831672],"genre_scores_gemma":[0.3701363,0.4462026,0.01045064,0.1388476,0.02227656,0.0002471299,0.002014592,0.0003747781,0.009449678],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.0104866,"threshold_uncertainty_score":0.05113614,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4414057587","doi":"10.58931/cht.2025.4s0570","title":"Expert Discussion: Building Unique Networks and Partnerships to Bring Novel Therapies to Remote Patients","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Ottawa Hospital","funders":"McMaster University; University of Ottawa","keywords":"MEDLINE; Raising (metalworking); Patient care; Patient privacy; Best practice; Key (lock)","authors":[{"name":"Arleigh McCurdy","is_ca":true},{"name":"Nicole Laferriere","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03386660563387316,"gpt":0.3202892960625872,"spread":0.286422690428714,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01587062,0.0008781641,0.0008293406,0.0008129349,0.007504747,0.005245613,0.003199792,0.02176235,0.0325596],"category_scores_gemma":[0.07705226,0.000461645,0.001516404,0.0008498945,0.004362995,0.006993874,0.004938161,0.02077819,0.007694668],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01126241,"about_ca_system_score_gemma":0.03755565,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04712173,"about_ca_topic_score_gemma":0.09361909,"domain_scores_codex":[0.9849002,0.00509784,0.0009685609,0.001363005,0.005143784,0.002526639],"domain_scores_gemma":[0.909933,0.02305822,0.002455753,0.001599963,0.0417027,0.02125038],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000008095423,0.000006327708,0.0001749041,0.0000752058,0.000004486863,0.0001131354,0.0001681408,0.00002567629,0.00004233515,0.0009616103,0.9910936,0.007326528],"study_design_scores_gemma":[0.00003594306,0.0000145285,0.0003276324,0.000819888,0.00001831646,0.0005728317,0.001457551,0.0001006719,0.0001015724,0.003240202,0.9932731,0.00003770654],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0001997392,0.002281634,0.0003988833,0.9688706,0.02322684,0.00003778527,0.00009533393,0.00004165423,0.004847395],"genre_scores_gemma":[0.008386657,0.009419606,0.001781701,0.9373484,0.0267739,0.0001283128,0.0002008722,0.0000581286,0.01590247],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.04712173,"threshold_uncertainty_score":0.1089227,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384134428","doi":"10.58931/cht.2023.2124","title":"Tyrosine kinase inhibitors for the frontline management of CML: an overview","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Bosutinib; Nilotinib; Dasatinib; Medicine; Imatinib; Ponatinib; Tyrosine kinase; Myeloid leukemia; Tyrosine-kinase inhibitor; Drug holiday; Internal medicine; Oncology; Population; Pharmacology; Immunology; Cancer","authors":[{"name":"Dennis Dong Hwan Kim","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04892717281739035,"gpt":0.3194743769551006,"spread":0.2705472041377102,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005982863,0.0005908326,0.0004962027,0.001852433,0.0003531798,0.0009875882,0.0004896891,0.0008611086,0.002962361],"category_scores_gemma":[0.0005095923,0.0001413993,0.0004652044,0.001263182,0.0002603778,0.001111063,0.0004249589,0.001920989,0.001075105],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001145691,"about_ca_system_score_gemma":0.00167751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00314142,"about_ca_topic_score_gemma":0.01430428,"domain_scores_codex":[0.9997732,0.00004168481,0.00002470471,0.00002385166,0.0001009149,0.00003563244],"domain_scores_gemma":[0.9997318,0.00008341774,0.00003729001,0.000004963122,0.00008969685,0.00005267803],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001039977,0.0001285376,0.0005786744,0.003977493,0.00006282226,0.0004125031,0.00008187904,0.0002355311,0.001425705,0.004277827,0.04546273,0.9432522],"study_design_scores_gemma":[0.0000330359,0.0002230144,0.001855333,0.002347576,0.0001015901,0.002257702,0.00006995963,0.0001742744,0.0003295725,0.001263642,0.9913293,0.00001494076],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005074063,0.9905751,0.0003810012,0.002876956,0.0003105993,0.00001895051,0.00002744732,0.00001511702,0.005287567],"genre_scores_gemma":[0.002058292,0.9944622,0.000878434,0.0009592746,0.0004910317,0.00001331113,0.00004787361,0.00000262253,0.001086968],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00314142,"threshold_uncertainty_score":0.009910047,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4403622133","doi":"10.58931/cht.2024.3254","title":"High-Risk Myeloma: Definitions and Treatments","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine","authors":[{"name":"Rintu Sharma","is_ca":true},{"name":"Karla Alexandra Sánchez Hernández","is_ca":true},{"name":"Guido Lancman","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02839632916491848,"gpt":0.2820652679824287,"spread":0.2536689388175102,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002995402,0.0009831678,0.001233803,0.003711174,0.001593439,0.00251016,0.002033619,0.001590527,0.002902894],"category_scores_gemma":[0.004313123,0.0002997115,0.0009315286,0.005155628,0.002206807,0.002077441,0.003531373,0.004100987,0.001407059],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005249897,"about_ca_system_score_gemma":0.007215955,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009200086,"about_ca_topic_score_gemma":0.008867993,"domain_scores_codex":[0.9979411,0.0005794808,0.0004606452,0.0002429662,0.0005301402,0.0002456706],"domain_scores_gemma":[0.9980515,0.0002107853,0.0004859535,0.00006871397,0.0006519697,0.0005310753],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004718541,0.0004944153,0.03039131,0.004265837,0.0001392623,0.001311377,0.001580127,0.001953311,0.001334269,0.1651788,0.2845089,0.5083705],"study_design_scores_gemma":[0.00008588727,0.0001896381,0.02368948,0.006624886,0.0001149511,0.007843881,0.001171393,0.0007880703,0.0003612773,0.05566782,0.9033709,0.0000919253],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01519185,0.7889432,0.01702847,0.08842569,0.005436148,0.001097181,0.002543345,0.0002310568,0.08110311],"genre_scores_gemma":[0.1503643,0.7229906,0.04991399,0.03327848,0.01569127,0.002109805,0.009860108,0.0002330739,0.01555841],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.009200086,"threshold_uncertainty_score":0.03809088,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4406091184","doi":"10.58931/cht.2024.3358","title":"Front-line Treatment of Older Patients with Hodgkin Lymphoma","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Front line; Hodgkin lymphoma; Medicine; Lymphoma; Oncology; Internal medicine; History; Archaeology","authors":[{"name":"Kelly Davison","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009216902251404107,"gpt":0.2385287447118827,"spread":0.2293118424604785,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000257958,0.0001092405,0.0002912304,0.0001839866,0.0002566237,0.0002602926,0.0001214777,0.0001853959,0.0014825],"category_scores_gemma":[0.0007911838,0.00006046119,0.0002275383,0.0002007077,0.00007330634,0.0002875551,0.000251431,0.0004017163,0.0004036152],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003843894,"about_ca_system_score_gemma":0.0002474251,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001064905,"about_ca_topic_score_gemma":0.004148678,"domain_scores_codex":[0.9998947,0.000026179,0.00001303852,0.0000109327,0.00002449132,0.00003067848],"domain_scores_gemma":[0.999703,0.00003546389,0.00007678881,0.00001085508,0.00004553254,0.000128349],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00700421,0.0008841287,0.349441,0.0009190894,0.0003012489,0.002739437,0.0008059686,0.0005198526,0.009214353,0.0004731579,0.02275212,0.6049454],"study_design_scores_gemma":[0.001064295,0.007290911,0.8775544,0.0009886816,0.0005882724,0.00858292,0.0007127565,0.001039872,0.00191922,0.001282858,0.09894017,0.00003566424],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"other","genre_scores_codex":[0.9429866,0.03903548,0.0006313129,0.002830673,0.0004369912,0.0001278873,0.0007004132,0.00004609215,0.0132046],"genre_scores_gemma":[0.9806425,0.01148887,0.000604602,0.003778639,0.0004753004,0.00005841905,0.0009547761,0.000007739647,0.001989201],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.0014825,"threshold_uncertainty_score":0.004959404,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4414384080","doi":"10.58931/cht.2025.4273","title":"Intensive Versus Non-intensive Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Venetoclax; Myeloid leukemia; Regimen; Clinical trial; Azacitidine; Chemotherapy; Chemotherapy regimen; Drug; Leukemia","authors":[{"name":"Karen Yee","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01333109663316175,"gpt":0.2816588606524685,"spread":0.2683277640193067,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001592972,0.0001834706,0.0007474145,0.0002667333,0.0002423876,0.0006000744,0.0003132268,0.0006056259,0.00347353],"category_scores_gemma":[0.002985645,0.00009863707,0.001367546,0.0003556908,0.0003734702,0.0008972461,0.0005173575,0.0009842152,0.0003189924],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004155453,"about_ca_system_score_gemma":0.0004013019,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003777877,"about_ca_topic_score_gemma":0.001261505,"domain_scores_codex":[0.9985955,0.0007011665,0.0001756408,0.0002508006,0.0001411184,0.0001357956],"domain_scores_gemma":[0.9982361,0.0007570622,0.0004938854,0.000140592,0.00004674792,0.0003257047],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.4357468,0.003295335,0.2997138,0.001615575,0.005783236,0.0002621789,0.0003665896,0.001495598,0.00307395,0.002418187,0.006287997,0.2399408],"study_design_scores_gemma":[0.03554139,0.1465777,0.7784754,0.0005753928,0.004437933,0.0007369651,0.0005896381,0.003293436,0.001451934,0.004138532,0.02409719,0.00008440459],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.9827659,0.01031313,0.0007263463,0.001033656,0.0004305479,0.0003442262,0.001159965,0.00001839923,0.003207936],"genre_scores_gemma":[0.9950756,0.0015723,0.0003874983,0.001055542,0.0003490451,0.0002557697,0.0008500806,0.000003995644,0.0004501449],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.00347353,"threshold_uncertainty_score":0.0116201,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4409994026","doi":"10.58931/cht.2025.4165","title":"Front-line Treatment of B-cell Acute Lymphoblastic Leukemia in Canada: Current Strategies and Evolving Paradigms","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Dalhousie University","funders":"","keywords":"Front line; Current (fluid); Line (geometry); Front (military); Computer science; Political science; Geography; Engineering; Mathematics; Electrical engineering; Law; Meteorology","authors":[{"name":"Curtis Marcoux","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01293867920188749,"gpt":0.2687941567114983,"spread":0.2558554775096107,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001714844,0.000477732,0.0006859694,0.001616932,0.00164866,0.002191381,0.001258173,0.0005647401,0.004275823],"category_scores_gemma":[0.002914893,0.000159822,0.0005504361,0.003767251,0.001058886,0.0008790817,0.001004666,0.00208938,0.0005745529],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.04149311,"about_ca_system_score_gemma":0.09439704,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.8919747,"about_ca_topic_score_gemma":0.9443586,"domain_scores_codex":[0.9987664,0.0001761908,0.0001052626,0.00009468744,0.0006004044,0.0002570751],"domain_scores_gemma":[0.9977334,0.0002024845,0.0001874194,0.00002989591,0.001416662,0.0004300815],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003334532,0.0001010698,0.007686674,0.006827095,0.000148799,0.0005138886,0.0008050289,0.001393075,0.001206936,0.01303374,0.1024316,0.8655187],"study_design_scores_gemma":[0.0001472413,0.0001498566,0.02595979,0.009330257,0.0003490256,0.0009138465,0.001335618,0.000584168,0.0009815907,0.003456926,0.9567181,0.00007351981],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.008282105,0.9276748,0.001303108,0.03832496,0.0008180508,0.0001172475,0.001102639,0.0001032507,0.02227383],"genre_scores_gemma":[0.0396859,0.9463187,0.003685814,0.006064053,0.0003890458,0.00005859111,0.001151314,0.00003593653,0.00261074],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1080253,"threshold_uncertainty_score":0.3010551,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4408507497","doi":"10.58931/cht.2025.4s0262","title":"Momelotinib Usage Within Our Current Canadian Myelofibrosis Armamentarium","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Calgary","funders":"","keywords":"Myelofibrosis; Current (fluid); Medicine; Internal medicine; Engineering","authors":[{"name":"Sonia Cerquozzi","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01858711002478022,"gpt":0.3005025020663963,"spread":0.2819153920416161,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005877569,0.0003424633,0.0003614558,0.0006627103,0.001788355,0.001255071,0.0007671991,0.0006272855,0.02047403],"category_scores_gemma":[0.001633454,0.0001060808,0.0003939284,0.001407973,0.0003939126,0.0004834819,0.0006531747,0.001371353,0.002213218],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01597522,"about_ca_system_score_gemma":0.02266154,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.512796,"about_ca_topic_score_gemma":0.7536124,"domain_scores_codex":[0.9995288,0.00005424742,0.00002616678,0.00007626249,0.0001750511,0.0001395372],"domain_scores_gemma":[0.9986354,0.00005901592,0.000122208,0.00002700786,0.0004381949,0.0007181168],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.001009504,0.0002326045,0.02605047,0.0008342694,0.0001863176,0.001071586,0.0003248423,0.0009974347,0.005665343,0.009192915,0.3380294,0.6164052],"study_design_scores_gemma":[0.0002417154,0.0001898821,0.02813996,0.000543255,0.0001621713,0.001720728,0.0001418772,0.0003140021,0.0009717332,0.0007995066,0.9667359,0.00003927196],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"other","genre_gemma":"empirical","genre_scores_codex":[0.1316023,0.2051595,0.004208453,0.1116446,0.003284734,0.0006692666,0.01662683,0.00126002,0.5255442],"genre_scores_gemma":[0.6927046,0.1246307,0.01006287,0.0601767,0.002937525,0.0004062655,0.01817839,0.0003802908,0.09052271],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.487204,"threshold_uncertainty_score":0.9801464,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4409993061","doi":"10.58931/cht.2025.4167","title":"Diagnosis and Management of Small Lymphocytic Lymphoma (SLL)Versus Chronic Lymphocytic Leukemia","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Lymphoma; Leukemia; Oncology; Immunology","authors":[{"name":"Anthea Peters","is_ca":false},{"name":"Robert Puckrin","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02322234478264082,"gpt":0.2895352835417574,"spread":0.2663129387591165,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00218995,0.0002423613,0.0007325718,0.0009672375,0.00107919,0.001653934,0.0006206453,0.0008213487,0.001238685],"category_scores_gemma":[0.006393983,0.0001374562,0.0002465831,0.0006348142,0.001557916,0.0008759646,0.001413255,0.001690966,0.0003197942],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003424308,"about_ca_system_score_gemma":0.004226325,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01152778,"about_ca_topic_score_gemma":0.02573389,"domain_scores_codex":[0.99839,0.0005427097,0.0001867753,0.0001509412,0.0004696618,0.0002600004],"domain_scores_gemma":[0.9986936,0.0003719106,0.0002533686,0.00003006031,0.0002464629,0.0004045959],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001244219,0.0002184504,0.07252656,0.000809209,0.00008695781,0.0077374,0.001308259,0.001067809,0.004847084,0.0131949,0.03624938,0.8607097],"study_design_scores_gemma":[0.001072422,0.003376651,0.2425105,0.01189429,0.0003963714,0.09962209,0.01233734,0.003832964,0.004504709,0.02980519,0.5903736,0.0002738843],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.2398684,0.5001953,0.01446905,0.127182,0.005015683,0.0004036519,0.0003407704,0.0002355332,0.1122896],"genre_scores_gemma":[0.8759167,0.08909731,0.007228528,0.0179911,0.006619765,0.0001594918,0.0003539598,0.00005060407,0.002582566],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01152778,"threshold_uncertainty_score":0.02484518,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384463934","doi":"10.58931/cht.2022.1213","title":"Multiple myeloma management: What comes after lenalidomide-based therapy?","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Monoclonal antibody; Quality of life (healthcare); Oncology; Internal medicine; Pharmacology; Antibody; Immunology","authors":[{"name":"Martha Louzada","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02060857983614805,"gpt":0.2658410217929562,"spread":0.2452324419568082,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007008696,0.0008116574,0.003490864,0.001492265,0.002269796,0.006180427,0.002228139,0.00606173,0.005611465],"category_scores_gemma":[0.01707028,0.0003773464,0.001647531,0.00150223,0.003434462,0.009023856,0.002179717,0.01319016,0.002055189],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003604149,"about_ca_system_score_gemma":0.005595436,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008181036,"about_ca_topic_score_gemma":0.02899519,"domain_scores_codex":[0.9967944,0.0009923737,0.000483411,0.0003256241,0.001033885,0.0003703363],"domain_scores_gemma":[0.9875618,0.00528968,0.0009534882,0.0002275449,0.003872754,0.002094704],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006808743,0.0002497488,0.004378467,0.004057184,0.0003135252,0.001427965,0.000530596,0.0004868589,0.0003597187,0.007143158,0.2300005,0.7503714],"study_design_scores_gemma":[0.0003431095,0.0009306443,0.01510518,0.03921224,0.0008216519,0.007586634,0.007058486,0.0009739471,0.0004014449,0.04099032,0.8863109,0.0002653892],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001421649,0.7696528,0.0005041961,0.2173044,0.007354976,0.00002201247,0.00009503523,0.00004940497,0.003595514],"genre_scores_gemma":[0.02294503,0.8155484,0.001938779,0.1023808,0.05478644,0.00005773062,0.0002518876,0.00005871815,0.00203232],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.008181036,"threshold_uncertainty_score":0.03706598,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4403622129","doi":"10.58931/cht.2024.3255","title":"Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia After BTK Inhibitor and/or BCL-2 Inhibitor Failure","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Chronic lymphocytic leukemia; Refractory (planetary science); Bruton's tyrosine kinase; Ibrutinib; Medicine; Internal medicine; Cancer research; Leukemia; Biology; Receptor","authors":[{"name":"Sue Robinson","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01358765583586513,"gpt":0.2729650758220165,"spread":0.2593774199861514,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003518441,0.0002527078,0.0005314848,0.000449114,0.0003470871,0.0004751029,0.0003091119,0.0004517544,0.002590686],"category_scores_gemma":[0.0005209655,0.00006538459,0.0004342615,0.0002578849,0.0002225054,0.0003297988,0.0003871912,0.0008344074,0.001088348],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005929414,"about_ca_system_score_gemma":0.000374338,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005393308,"about_ca_topic_score_gemma":0.002078965,"domain_scores_codex":[0.9998637,0.00003790229,0.00001234441,0.00001550658,0.00002485883,0.00004551481],"domain_scores_gemma":[0.9998589,0.00003320484,0.00002887215,0.000009094336,0.00001798688,0.00005198807],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004994039,0.0007076818,0.01446193,0.001499658,0.0002853281,0.0140577,0.0004309014,0.001716522,0.0188875,0.003053273,0.05478193,0.8851236],"study_design_scores_gemma":[0.003971424,0.01513424,0.07312614,0.003837469,0.0005237897,0.08092078,0.0006320791,0.005564231,0.02334429,0.01331082,0.7794943,0.000140502],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.4967274,0.3805872,0.01456372,0.01404821,0.002629383,0.0007945894,0.001396294,0.001390074,0.08786308],"genre_scores_gemma":[0.9088261,0.06127083,0.004049057,0.007997942,0.001401881,0.0003104323,0.002015744,0.0001129811,0.014015],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.002590686,"threshold_uncertainty_score":0.008666694,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4414384116","doi":"10.58931/cht.2025.4275","title":"Concise Review of Chronic Myelomonocytic Leukemia in Canada in 2025","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Chronic myelomonocytic leukemia; Myeloid leukemia; Incidence (geometry); Myeloproliferative neoplasm; Myelodysplastic syndromes; Leukemia","authors":[{"name":"Jacqueline Costello","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01274919328756639,"gpt":0.2887835138178179,"spread":0.2760343205302515,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001105921,0.0008252839,0.001187446,0.007212549,0.001060053,0.002135099,0.001197227,0.001546001,0.01058622],"category_scores_gemma":[0.004279458,0.0003260305,0.0005331191,0.008362486,0.0008034272,0.001477751,0.0009631705,0.001948703,0.003097604],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01157831,"about_ca_system_score_gemma":0.03127888,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.3849673,"about_ca_topic_score_gemma":0.6153303,"domain_scores_codex":[0.9992234,0.00007849143,0.0001178543,0.00006479216,0.0004216523,0.00009383092],"domain_scores_gemma":[0.9949434,0.0003291663,0.0002991229,0.00004291695,0.003628956,0.0007563612],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004679484,0.00001644654,0.0007135664,0.006622673,0.0000451739,0.0005045185,0.0001081348,0.0001414664,0.0002072612,0.001852437,0.7517624,0.2379792],"study_design_scores_gemma":[0.000005568396,0.00001015016,0.001281354,0.004062304,0.00003696273,0.0007877582,0.00008008078,0.00002096922,0.00003038292,0.0001607876,0.9935081,0.00001554183],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002178261,0.969296,0.0001000786,0.01030208,0.01348797,0.00002548386,0.000479,0.00002141924,0.006070062],"genre_scores_gemma":[0.00160012,0.9804273,0.0002141011,0.004913622,0.007963557,0.00001503686,0.0006393859,0.00001110749,0.004215742],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3849673,"threshold_uncertainty_score":0.7654531,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384461365","doi":"10.58931/cht.2022.1s1029","title":"Treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Centre Hospitalier de l’Université de Montréal; Cégep de l'Abitibi Témiscamingue; Juravinski Cancer Centre; Université du Québec en Abitibi-Témiscamingue","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Diffuse large B-cell lymphoma; Medicine; Lymphoma; Oncology; Refractory (planetary science); Adverse effect; Internal medicine; Intensive care medicine","authors":[{"name":"Ronan Foley","is_ca":true},{"name":"Carolyn Owen","is_ca":true},{"name":"Samer Tabchi","is_ca":true},{"name":"Ghazaleh Shoja E Razavi","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01298582522957346,"gpt":0.2420465072915202,"spread":0.2290606820619467,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001990633,0.0001571426,0.0003701511,0.0003590352,0.0004046001,0.0005270161,0.0003464629,0.0004675011,0.008897993],"category_scores_gemma":[0.0004590089,0.00005676899,0.0003675885,0.0002655134,0.000160619,0.000411106,0.0003385103,0.001065123,0.001444446],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005293657,"about_ca_system_score_gemma":0.0005640832,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001639581,"about_ca_topic_score_gemma":0.005860683,"domain_scores_codex":[0.9998955,0.00002240402,0.00001168683,0.00001221079,0.00002814761,0.00003007084],"domain_scores_gemma":[0.9998711,0.0000286693,0.00002155448,0.0000031954,0.00001639297,0.00005897951],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001122182,0.0003551546,0.007669423,0.001492218,0.0001406226,0.00296872,0.0002396464,0.001165928,0.004943709,0.003844392,0.1257944,0.8502636],"study_design_scores_gemma":[0.001136094,0.001353965,0.02992324,0.004081764,0.0003906309,0.01945839,0.0007879964,0.001256345,0.002741071,0.01257398,0.9262404,0.00005602597],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1019173,0.6796062,0.006817203,0.06958073,0.001880312,0.000300512,0.002043587,0.0003532604,0.1375009],"genre_scores_gemma":[0.6071047,0.3251369,0.008926464,0.02837201,0.003721295,0.0003889567,0.004401465,0.00009913163,0.0218491],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.008897993,"threshold_uncertainty_score":0.02976674,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4384463914","doi":"10.58931/cht.2022.1215","title":"With great power comes great responsibility: Managing side effects of novel treatments in chronic lymphocytic leukemia (CLL)","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Hematologist; Rating scale; Clinical trial; Intensive care medicine; Leukemia; Psychology; Disease","authors":[{"name":"Versha Banerji","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01376682647667075,"gpt":0.270123220714966,"spread":0.2563563942382953,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006693273,0.000315609,0.0007204085,0.0006098796,0.001258557,0.002979497,0.0007122407,0.00107013,0.003512423],"category_scores_gemma":[0.01890567,0.0001291082,0.0005056901,0.0005509894,0.001182913,0.00185389,0.001353805,0.003051393,0.0008371374],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002499373,"about_ca_system_score_gemma":0.005439391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00484666,"about_ca_topic_score_gemma":0.01811022,"domain_scores_codex":[0.9963595,0.001885559,0.000231272,0.0001520201,0.001163581,0.0002080647],"domain_scores_gemma":[0.9915889,0.003705228,0.001540304,0.0002947266,0.001646536,0.001224278],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004191226,0.0002233113,0.01047106,0.000687682,0.0001607185,0.0005969023,0.0006421514,0.000695117,0.0009825811,0.003625646,0.07158637,0.9099094],"study_design_scores_gemma":[0.0007380446,0.00360207,0.07286733,0.005353116,0.0008131193,0.008764725,0.003688236,0.004588163,0.003732146,0.04752694,0.8480701,0.0002559834],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.08026915,0.3951425,0.01994806,0.4106665,0.004483145,0.0003474626,0.0003464691,0.0005706658,0.08822602],"genre_scores_gemma":[0.6277093,0.2308775,0.0393056,0.06856138,0.01032306,0.0003783536,0.0004491847,0.0002841439,0.02211142],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.006693273,"threshold_uncertainty_score":0.03539783,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4414384075","doi":"10.58931/cht.2025.4272","title":"Front-line Treatment for Chronic Lymphocytic Leukemia in 2025: Finite Duration Versus Continuous Treatment","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Chronic lymphocytic leukemia; Malignancy; Disease; Lymphoproliferative disease; Tyrosine kinase; Hematologic malignancy; Leukemia","authors":[{"name":"Chathuri Abeyakoon","is_ca":false},{"name":"Abi Vijenthira","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03534443402336911,"gpt":0.3317999994173451,"spread":0.296455565393976,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001913425,0.0002173574,0.0008476756,0.0005788711,0.0002495607,0.001241625,0.0007671206,0.0005929543,0.004263262],"category_scores_gemma":[0.002258044,0.0001026546,0.0007151378,0.0008155419,0.000337967,0.0008080513,0.0003407471,0.001153263,0.0005739937],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002981193,"about_ca_system_score_gemma":0.002469486,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01097427,"about_ca_topic_score_gemma":0.04804362,"domain_scores_codex":[0.9993231,0.0001863598,0.00009563674,0.00007559272,0.0002432874,0.00007604282],"domain_scores_gemma":[0.9990768,0.0004180832,0.0001630129,0.00001873861,0.0002289211,0.00009441692],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001358491,0.00007590258,0.001637148,0.009728788,0.0003193354,0.0001014575,0.0001017838,0.0002869006,0.0009097914,0.004490342,0.01863394,0.9623561],"study_design_scores_gemma":[0.001303581,0.001618328,0.01865441,0.02937765,0.001896339,0.001542616,0.0003654074,0.000446856,0.001058208,0.003935074,0.9397202,0.00008134646],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002610377,0.9891571,0.0002244953,0.003055489,0.0003831353,0.00002226886,0.0001200586,0.000006621367,0.004420538],"genre_scores_gemma":[0.04395239,0.9466775,0.001167521,0.004593835,0.0008727537,0.00006479958,0.0004653145,0.0000111708,0.002194736],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01097427,"threshold_uncertainty_score":0.02182078,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417129959","doi":"10.58931/cht.2025.4377","title":"New Developments in the Front‑line Treatment of Advanced Stage Classic Hodgkin Lymphoma: A Canadian Perspective","year":2025,"lang":"","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Perspective (graphical); Stage (stratigraphy); Clinical trial; Hodgkin lymphoma; MEDLINE; Paradigm shift","authors":[{"name":"Jowon L. Kim","is_ca":true},{"name":"Kerry J. Savage","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01541830916446705,"gpt":0.2833311281488873,"spread":0.2679128189844202,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002885705,0.0005416833,0.0006359821,0.002080831,0.001683661,0.002319254,0.001171019,0.001330667,0.01003468],"category_scores_gemma":[0.004244867,0.0001820933,0.000525382,0.002657357,0.001604149,0.001575074,0.001111632,0.003946196,0.001390484],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01819736,"about_ca_system_score_gemma":0.04132979,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.6286317,"about_ca_topic_score_gemma":0.8066137,"domain_scores_codex":[0.9986959,0.0001711502,0.00009227428,0.0001065445,0.000688455,0.0002456766],"domain_scores_gemma":[0.9939258,0.0004899048,0.0002769845,0.00006191609,0.004145073,0.001100313],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003764947,0.000114041,0.003662724,0.004105666,0.0001082126,0.0008981734,0.0006937085,0.0008227777,0.002382847,0.0248512,0.3080387,0.6539454],"study_design_scores_gemma":[0.00005933328,0.0000861492,0.003413256,0.002238524,0.000108832,0.0006156935,0.0003635542,0.0002031482,0.0003385151,0.002175144,0.9903581,0.00003978774],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002702784,0.8015097,0.001656281,0.1511439,0.005955169,0.00005040755,0.0004667152,0.0001111969,0.03640378],"genre_scores_gemma":[0.03102737,0.9288374,0.003953884,0.02377016,0.004837226,0.00002971935,0.000451597,0.00006038683,0.007032322],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3713683,"threshold_uncertainty_score":0.7471108,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4406091245","doi":"10.58931/cht.2024.3356","title":"Relapsed or Refractory Mantle Cell Lymphoma: Available and Emerging Therapies","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Mantle cell lymphoma; Refractory (planetary science); Mantle (geology); Medicine; Cancer research; Lymphoma; Oncology; Geology; Internal medicine; Geochemistry; Astrobiology; Biology","authors":[{"name":"Jean‐Nicolas Champagne","is_ca":true},{"name":"Diego Villa","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01532409385713713,"gpt":0.2494044735073183,"spread":0.2340803796501811,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001095395,0.0004228556,0.001175062,0.0007608762,0.0002549789,0.00117606,0.0008273437,0.000706414,0.002839688],"category_scores_gemma":[0.0007888343,0.0001866805,0.0006814555,0.0005669298,0.0005778932,0.001319657,0.0007079833,0.002839247,0.0008930495],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000867861,"about_ca_system_score_gemma":0.0005434054,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003791786,"about_ca_topic_score_gemma":0.001882982,"domain_scores_codex":[0.9996594,0.00007910165,0.00004341806,0.00006788421,0.00008828383,0.00006196285],"domain_scores_gemma":[0.999556,0.000167964,0.00007328385,0.00001994315,0.00008800974,0.00009470447],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008024083,0.0004014591,0.001396082,0.004178226,0.0001725185,0.0007407799,0.0001203622,0.0008817749,0.003271767,0.004715777,0.02326245,0.9600563],"study_design_scores_gemma":[0.001293409,0.002916664,0.008034882,0.009853736,0.0008790285,0.008517818,0.0004322169,0.002571654,0.002228243,0.01368732,0.949489,0.00009604428],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.005024709,0.9875739,0.0004458717,0.004056206,0.0003515466,0.00001469567,0.00005884465,0.00004548056,0.002428782],"genre_scores_gemma":[0.04554258,0.9414241,0.001856996,0.006550163,0.002409884,0.0000538581,0.0004132529,0.00002701493,0.00172221],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002839688,"threshold_uncertainty_score":0.009499669,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4409987547","doi":"10.58931/cht.2025.4164","title":"Central Nervous System Relapse of Aggressive B-cell Lymphoma: Insights Into Current Treatment Approaches","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Royal College of Pathologists of Australasia","keywords":"Lymphoma; Central nervous system; Medicine; Current (fluid); Aggressive lymphoma; Oncology; Neuroscience; Intensive care medicine; Internal medicine; Biology; Rituximab; Engineering","authors":[{"name":"Chathuri Abeyakoon","is_ca":true},{"name":"Anca Prica","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02649810773108343,"gpt":0.2737271228354629,"spread":0.2472290151043795,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002363433,0.0006573591,0.001397731,0.001612954,0.0003998697,0.001958343,0.001565864,0.00116062,0.002473835],"category_scores_gemma":[0.003299614,0.0002771285,0.0009988967,0.0007768391,0.0008611447,0.002202437,0.0009932346,0.00332905,0.0007820901],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001707756,"about_ca_system_score_gemma":0.002364688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001807657,"about_ca_topic_score_gemma":0.004196419,"domain_scores_codex":[0.9993229,0.0002131494,0.0001094725,0.000131856,0.0001325041,0.00009015016],"domain_scores_gemma":[0.9982328,0.000919815,0.0001920323,0.00005839968,0.0004246559,0.000172171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003637089,0.0002979214,0.002465421,0.005066121,0.0001822347,0.0004043664,0.0001962218,0.001222602,0.0008409545,0.006697948,0.0166208,0.9656417],"study_design_scores_gemma":[0.0005552667,0.00269924,0.01176949,0.03641187,0.001628553,0.006385266,0.001704077,0.006697083,0.00170592,0.03901592,0.891223,0.0002042383],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002243344,0.9862307,0.001104242,0.007645451,0.0004020953,0.0000259814,0.00005207398,0.00003796471,0.002258125],"genre_scores_gemma":[0.02735081,0.9617927,0.003605092,0.003943047,0.002208289,0.0001187499,0.0002463445,0.00001981635,0.0007151701],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002473835,"threshold_uncertainty_score":0.01249915,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}